Scaling Your Peptide Practice: Informed Consent Essentials

Defining the Off-Label Status

Many peptides lack specific FDA approval for every condition they treat. Your consent form must explicitly state if a medication is being used off-label. Patients need to acknowledge that the usage deviates from standardized FDA indications.

• Include a clear statement on the FDA status of the specific peptide.
• Define what off-label use means in plain English.
• Require a specific initial next to the off-label disclosure.
• Document why the practitioner chose this specific therapy.

Detailed Side Effect Disclosures

Vague descriptions of side effects will not protect your clinic. You need to list common and severe reactions associated with GLP-1s and longevity peptides. The form should be updated as new clinical data emerges.

• List gastrointestinal issues common to GLP-1 therapies.
• Include rare but serious risks like pancreatitis or thyroid tumors.
• Explain potential injection site reactions.
• Detail contraindications such as personal or family history of specific cancers.

Compounding Pharmacy Transparency

If you source from a compounding pharmacy, the patient must know. Federal regulations require disclosure that compounded drugs are not FDA-approved in the same manner as brand-name biologics. This transparency builds trust and meets legal requirements.

• State that the medication is prepared by a licensed compounding pharmacy.
• Confirm the pharmacy follows USP 797 or 800 standards.
• Explain that compounding is necessary due to shortages or customization.
• Clarify that compounded versions are not identical to brand-name retail versions.

Financial and Operational Terms

Prevent billing disputes by including clear financial terms. Patients should understand the costs, refill procedures, and communication expectations. This section reduces administrative friction for your staff.

The Role of Medical Oversight

A consent form should emphasize that the patient is under active medical supervision. It must outline the necessity of follow-up appointments and blood work. If a patient fails to comply with monitoring, the clinic must have the right to terminate treatment.

• Mandate regular lab testing for ongoing prescriptions.
• Require patients to report new medications or health status changes.
• Outline the process for emergency contact and non-urgent questions.
• Establish the provider's right to stop treatment for non-compliance.